MDS Chromosome and Gene Anomaly Probe
Product Description: myelodysplastic syndrome
Applications: Hematological tumor
MDS chromosome and gene anomaly detection probe
1. Fleetness: Tissue probe hybridization time: 2 hours. Cell probe hybridization time: 1 hour.
2. Accuracy: Less non-specific background staining (dyeing). Increase difficult samples detection rate.
3. Reproducibility: Different laboratories test results are highly reproducible.
The kit uses orange-red fluorescent markers CSF1R, EGR1, D7S486, D7S522, D20S108, CEPY probes, and the probes are bound to the target detection site by in situ hybridization using green fluorescent markers D5S630, CEP7, CEP8, and CEPX probes. Under normal conditions (no gene deletion and chromosomal abnormalities), two orange-red signals and two green signals are shown under a fluorescence microscope. When there is a gene deletion, there will be a lack of green or orange-red signals, and when there is a chromosomal multibody, the centromere gene probe signal will increase. Detection of gene deletion and chromosomal abnormalities by this method is of great significance for the diagnosis, treatment and prognosis of clinical MDS.
Among the common chromosomal abnormalities in MDS patients, some chromosomal abnormalities have specific diagnostic value. Some patients with simple +8, 20q- or Y- are effective in immunosuppressive therapy, karyotyping is also of great value in the classification, treatment and prognosis of MDS, such as single Y-, 5q- or 20q-MDS Patients had a better prognosis, and patients with complex chromosomal abnormalities (≥3 abnormalities) or chromosome 7 abnormalities had a poor prognosis, and other abnormal patients had a moderate prognosis. NCCN and the “Chinese Expert Consensus for the Diagnosis and Treatment of Myelodysplastic Syndrome (2014 Edition)” recommend that all patients suspected of having MDS should have a chromosomal test, and fluorescent in situ hybridization probes (commonly abnormal sets of probes) are recommended. Abnormalities are important for the diagnosis, treatment, and prognosis of MDS.